FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
On December 4, US the Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab-zbco for adults with the following:
advanced, unresectable, or metastatic non-small cell lung cancer harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy, or
advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a NRG1 gene fusion with disease progression on or after prior systemic therapy.
In Person Meeting & NetworkingMay 6, 2026 at 8:00 AM EDT560 King Street, Charleston, SC, USAHyatt Place + Hyatt House Charleston - Historic District, Charleston
In Person Conference & ConventionApril 15, 2026 at 5:00 PM CDTPark Pl Blvd, St. Louis Park, MN, USADoubleTree by Hilton Hotel Minneapolis - Park Place, St. Louis Park
